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clothing, it is likely that the increases in waist
circumference are genuine.
Increases in waist circumference on current and
future morbidity should be a cause for concern. One
US study found that young people above the 90th cen-
tile for waist circumference had higher concentrations
of low density lipoprotein cholesterol, triglycerides,
and insulin and lower concentrations of high density
lipoprotein cholesterol than young people below the
10th centile.14 It is not known how early in life the
increases in waist circumference over the reference
values from 1977 and 1987 are detectable in a contem-
porary population, although we have observed similar
increases in children as young as 3 years (unpublished
observations).
The increase in waist circumference was appreci-
ably larger in females than in males, for reasons that
are unclear. Energy intake has decreased to a similar
extent in the sexes.7 It may be that levels of physical
activity have decreased faster in females than in males,
and central fatness may be related more to physical
activity than to energy intake.
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Views of doctors and managers on the doctor-manager
relationship in the NHS
Huw T O Davies, Claire-Louise Hodges, Thomas G Rundall
A well functioning relationship between doctors and
managers is crucial if government plans for “modern-
ising” the NHS are to deliver real service improve-
ments.1 2 We aimed to shed some light on current
perceptions of the doctor-manager relationship by
examining areas of convergence or divergence of views
among a large sample of doctors and managers in the
NHS.
Participants, methods, and results
We conducted a postal questionnaire survey in NHS
acute trusts across Great Britain during the summer of
2002. The survey included a census of chief executives
and medical directors (from 197 trusts), together with a
stratified cluster sample of both medical and
non-medical managers at directorate level (clinical
directors or their equivalent and non-medical directo-
rate managers or their equivalent) randomly selected
from 75 trusts. Comparisons between these different
role groups form the central part of the analysis; we
assessed variations across all four groups using 2 tests.
We received replies from 103 chief executives, 168
medical directors, 445 clinical directors (or equivalent),
and 376 non-medical directorate managers (or
equivalent). The response rate was 66% at board level
and 73% at directorate level, giving a total of 1092
respondents.
Overall, chief executives were the most optimistic
about the state of doctor-manager relationships, and
clinical directors the least. About three quarters
(78/103, 76%) of chief executives rated the quality of
current doctor-manager relationships as 4 or more on
a scale of 1 (poor) to 5 (excellent), compared with just
37% (164/443) of clinical directors. Further, 78% (80/
102) of chief executives thought that doctor-manager
relationships would improve over the next year,
compared with just 28% (123/439) of clinical directors
(indeed, 26% (113/439) of clinical directors thought
that the relationships would deteriorate). Differences
across all four groups were significant at P < 0.01.
Questions about specific aspects of the doctor-
manager relationship showed some areas of good
agreement but also highlighted issues where views
diverged significantly between the four groups (table).
Only rarely was the most obvious divide between those
medically qualified and those not. More often, the dif-
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ferences were between senior managers (board level)
and middle managers (directorate level). Most striking
was that clinical directors often seemed to have views
markedly divergent from—and much less positive
than—the views held across the other three groups.
Typically, clinical directors were the least impressed
with management and the most dissatisfied with the
role and influence of clinicians. For example, whereas
almost all (95% (610/640)) chief executives, medical
directors, and directorate managers agreed that “man-
agers allow doctors sufficient autonomy to practise
medicine effectively,” 27% of clinical directors disa-
greed. Further, as a group, clinical directors were less
likely (P < 0.01) than each of the other groups to agree
that “management staff in this hospital are consistently
of high quality” (53% v 77% (average across the other
three groups)), that “managers are well versed in clini-
cal activity” (47% v 81%), and that “doctors have
sufficient influence on hospital management” (48% v
85%). Indeed, for almost all positive statements about
doctor-manager relationships at least a quarter of
clinical directors disagreed. The only statement that
received near unanimous approval from clinical direc-
tors (90%) was “medical staff in this hospital are
consistently of high quality.”
Comment
Doctors and managers in the NHS are often
dissatisfied with doctor-manager relationships but
differ in their views depending on their role in the
organisation. In general, senior managers were more
positive than staff at directorate level, and lay managers
were more positive than medical managers. Clinical
directors (or those in equivalent roles) were easily the
most disaffected, with many holding negative opinions
about managers’ capabilities, the respective balance of
power and influence between managers and clinicians,
and the prospects for improved relations. Unless such
divergence is addressed, further difficulties in delivery
Agreement with statements about doctor-manager relationships among 1092 survey respondents. Values are the percentages (numbers) of respondents in
each group who agreed with given statement
Statements
Chief executives
(n=103)
Medical directors
(n=168)
Directorate managers
(n=376)
Clinical directors
(n=445)
Overall
(n=1092)
Issues of relative power
The relative power and influence between management and medical staff
is about right
74 (75) 73 (123) 54 (199) 45 (198) 55 (595) **
Doctors are adequately involved in hospital management activities 78 (79) 75 (124) 68 (253) 63 (282) 68 (738) **
Doctors have sufficient influence on hospital management 92 (95) 77 (127) 87 (320) 48 (211) 70 (753) **
Managers allow doctors sufficient autonomy to practise medicine
effectively
97 (99) 95 (157) 95 (354) 73 (317) 86 (927) **
Management do not exert pressure to reduce use of tests or services† 75 (76) 88 (147) 83 (306) 76 (330) 80 (859) **
Management do not exert pressure to discharge or transfer patients early† 50 (51) 52 (87) 49 (179) 55 (241) 52 (558)
Perceptions of staff calibre
Management staff in this hospital are consistently of high quality 81 (82) 70 (114) 78 (292) 53 (232) 67 (720) **
Medical staff in this hospital are consistently of high quality 92 (94) 91 (148) 85 (316) 90 (397) 88 (955) *
Managers are well versed in clinical activity 84 (85) 76 (124) 83 (311) 47 (206) 68 (726) **
Managers have confidence in clinical leadership capabilities 68 (70) 67 (111) 69 (253) 71 (310) 69 (744)
Doctors have confidence in management leadership capabilities 87 (89) 63 (105) 55 (202) 42 (184) 54 (580) **
Views on goals, decision making, and team working
Hospital managers and doctors are largely in agreement on the overall
goals of the institution
96 (99) 83 (140) 81 (302) 78 (343) 81 (884) **
Management is driven more by clinical rather than financial priorities† 78 (80) 44 (71) 53 (197) 24 (104) 42 (452) **
Managers and doctors focus together on patient need 87 (88) 80 (134) 82 (306) 61 (267) 74 (795) **
Doctors view the management decision making process to be fair 74 (75) 60 (99) 40 (148) 36 (159) 45 (481) **
Doctors generally are supportive of management decisions 90 (93) 77 (127) 64 (231) 52 (224) 63 (675) **
Doctors and managers work well together as a team 91 (94) 87 (141) 82 (303) 73 (315) 80 (853) **
Continuous improvement is undertaken on the basis of partnership and
teamwork
90 (92) 79 (131) 82 (305) 70 (303) 78 (831) **
Communication issues
Management is good at providing feedback to doctors about service
delivery
75 (76) 63 (104) 73 (272) 51 (223) 63 (675) **
Doctors are good at keeping management informed about service
development issues
66 (67) 55 (93) 42 (155) 56 (246) 52 (561) **
The use of clinical performance data stimulates good practice and
strengthens service management
93 (96) 86 (142) 84 (310) 74 (321) 81 (869) **
The availability of clinical performance data improves the doctor-manager
relationship
83 (84) 73 (121) 70 (257) 61 (266) 68 (728) **
Resource issues
There is an adequate number of consultants to provide quality patient care 32 (33) 24 (39) 41 (153) 14 (62) 27 (287) **
Within this organisation there are generally sufficient clinical resources 24 (25) 18 (29) 25 (92) 9 (38) 17 (184) **
Management is generally responsive to requests for additional clinical
resources
86 (87) 69 (114) 76 (282) 38 (167) 61 (650) **
Doctors prioritise effectively when making requests for additional
resources
39 (40) 32 (53) 23 (86) 47 (204) 36 (383) **
Some denominators are reduced because of missing data (never more than 3% for any individual question).
*P<0.05 for 2 test of equality across groups.
**P<0.01 for 2 test of equality across groups.
†These statements were “reverse worded,” and values have been adjusted accordingly.
Papers
627BMJ VOLUME 326 22 MARCH 2003 bmj.com
of the government’s ambitious agenda for modernisa-
tion are likely.3
Contributors: HTOD and TGR designed the study; C-LH
collected the data and did the analysis; HTOD led on writing the
paper, with substantial contributions from TGR and C-LH.
HTOD acts as guarantor.
Funding: Nuffield Trust, London, and the Commonwealth
Fund, New York. The guarantor accepts full responsibility for
the conduct of the study, had access to the data, and controlled
the decision to publish.
Competing interests: None declared.
1 Edwards N, Marshall M. Doctors and managers. BMJ 2003;326:116-7.
2 Protopsaltis G, Fulop N, Edwards N, Meara R. Failure and turnaround.
London: NHS Confederation, 2003.
3 McLellan A. A nasty kick in the ballots. Health Serv J 2002: 14 November,
pp18-19.
(Accepted 4 March 2003)
Evidence of Plasmodium falciparum malaria resistant to
atovaquone and proguanil hydrochloride: case reports
Anna Färnert, Johan Lindberg, Pedro Gil, Göte Swedberg, Yngve Berqvist, Mita M Thapar,
Niklas Lindegårdh, Sándor Berezcky, A Björkman
The increased spread of drug resistant malaria
highlights the need for alternatives for treatment and
chemoprophylaxis. The combination of atovaquone
and proguanil hydrochloride (Malarone, GlaxoSmith-
Kline, NC) has shown high efficacy against Plasmodium
falciparum with only mild side effects and has been reg-
istered for use in several countries, including Denmark,
Germany, Sweden, the United Kingdom, and the
United States.1 Treatment failures have been attributed
to suboptimal dosage, reinfections, or to a point muta-
tion in the cytochrome b gene.1 2 Bioavailability of
atovaquone depends on the concomitant intake of a
fatty diet, yet drug concentrations were not analysed in
these reports. We provide evidence of resistance in two
patients treated with atovaquone and proguanil hydro-
chloride for P falciparum infection.
Methods and results
In September 2000, two boys and their mother were
diagnosed as having P falciparum malaria at the univer-
sity hospital in Gothenburg, after returning from an
eight week visit to the Ivory Coast. They had taken
chloroquine weekly and proguanil daily for chemo-
prophylaxis against malaria. Case 1, the youngest boy
(18 months), had fever, convulsions, and 1% infected
erythrocytes. He was treated with atovaquone and pro-
guanil hydrochloride (table). His fever continued, and
Details of three patients treated with atovaquone and proguanil hydrochloride (Malarone; GlaxoSmithKline) for Plasmodium falciparum
malaria
Patients’ details Infected erythrocytes (%) No of tablets
Gene mutations*
Cytochrome b Dihydrofolate reductase
Case 1 (11 kg)
Day of presentation 1 2 Wild type Wild type
Days after presentation:
1 5 1
2 4 Mefloquine†
4 Gametocytes only
7 Gametocytes only Wild type Wild type
28 0
Case 2 (19 kg)
Day of presentation 0.5 1 Mutant type 1 Wild type
Days after presentation:
1 1
2 0.2 1
4 Gametocytes only Negative Negative
7 Gametocytes only Negative Negative
28 1.6 Mefloquine† Mutant type 1 Mutant type 2
Case 3 (101 kg)
Day of presentation Few rings 4 Mutant type 1 Wild type
Days after presentation:
1 4
2 0 4
3 Gametocytes only Mutant type 1 Negative
7 Gametocytes only Mutant type 1 Negative
28 0 Negative Negative
Mutant type 1=locus 268-Ser. Mutant type 2=loci 51-Ile, 59-Arg, and 108-Asn.
*Detected by polymerase chain reaction.
†Rescue treatment.
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